ALDH1A1 and ovarian carcinoma: Silencing ALDH1A1 using small interfering RNA can sensitise taxane- and platinum-resistant ovarian cancer cell lines to chemotherapy, suggesting a strategy of targeting ALDH1A1 to sensitise drug-resistant cells to chemotherapy.42 In addition, ALDH1A1 inhibitors targeting stem cell characteristics have been developed,43 for example, CM37.